Endothelin receptor antagonists: Errant letter removed
Okumaya devam et...
← Previous revision | Revision as of 03:08, 29 April 2024 |
| Line 210: | Line 210: |
| ====Endothelin receptor antagonists==== | ====Endothelin receptor antagonists==== |
| Moderate quality evidence suggests that endothelin receptor antagonists improve exercise capacity and decrease symptoms severity.<ref>{{cite journal | vauthors = Liu C, Chen J, Gao Y, Deng B, Liu K | title = Endothelin receptor antagonists for pulmonary arterial hypertension | journal = The Cochrane Database of Systematic Reviews | volume = 2021 | issue = 3 | pages = CD004434 | date = March 2021 | pmid = 33765691 | pmc = 8094512 | doi = 10.1002/14651858.CD004434.pub6 | collaboration = Cochrane Airways Group }}</ref> The dual (ET<sub>A</sub> and ET<sub>B</sub>) [[endothelin]] receptor antagonist [[bosentan]] was approved in 2001. [[Sitaxentan]] (Thelin) was approved for use in Canada, Australia, and the European Union,<ref name="Thelin">{{cite news |date=2008-05-30 |url=https://www.reuters.com/article/governmentFilingsNews/idUSBNG28335020070530 |title=UPDATE 1-Encysive gets Canadian approval for hypertension drug |newspaper=Reuters |access-date=2007-07-08 |url-status=live |archive-url=https://web.archive.org/web/2007070...e/governmentFilingsNews/idUSBNG28335020070530 |archive-date=2007-07-04 }}</ref> but not in the United States. In 2010, Pfizer withdrew Thelin worldwide because of fatal liver complications.{{cn|date=March 2024}} A similar drug, [[ambrisentan]] is sold under the brand name Letairis in the US by [[Gilead Sciences]].<ref>{{cite press release | title = U.S. Food and Drug Administration Approves Gilead's Letairis Treatment of Pulmonary Arterial Hypertension | publisher = [[Gilead Sciences]] | date = 2007-06-15 | url = http://www.gilead.com/wt/sec/pr_1016053 | access-date = 2007-06-16 | archive-url = https://web.archive.org/web/20070927064048/http://www.gilead.com/wt/sec/pr_1016053 | archive-date = 2007-09-27 }}</ref> s | Moderate quality evidence suggests that endothelin receptor antagonists improve exercise capacity and decrease symptoms severity.<ref>{{cite journal | vauthors = Liu C, Chen J, Gao Y, Deng B, Liu K | title = Endothelin receptor antagonists for pulmonary arterial hypertension | journal = The Cochrane Database of Systematic Reviews | volume = 2021 | issue = 3 | pages = CD004434 | date = March 2021 | pmid = 33765691 | pmc = 8094512 | doi = 10.1002/14651858.CD004434.pub6 | collaboration = Cochrane Airways Group }}</ref> The dual (ET<sub>A</sub> and ET<sub>B</sub>) [[endothelin]] receptor antagonist [[bosentan]] was approved in 2001. [[Sitaxentan]] (Thelin) was approved for use in Canada, Australia, and the European Union,<ref name="Thelin">{{cite news |date=2008-05-30 |url=https://www.reuters.com/article/governmentFilingsNews/idUSBNG28335020070530 |title=UPDATE 1-Encysive gets Canadian approval for hypertension drug |newspaper=Reuters |access-date=2007-07-08 |url-status=live |archive-url=https://web.archive.org/web/2007070...e/governmentFilingsNews/idUSBNG28335020070530 |archive-date=2007-07-04 }}</ref> but not in the United States. In 2010, Pfizer withdrew Thelin worldwide because of fatal liver complications.{{cn|date=March 2024}} A similar drug, [[ambrisentan]] is sold under the brand name Letairis in the US by [[Gilead Sciences]].<ref>{{cite press release | title = U.S. Food and Drug Administration Approves Gilead's Letairis Treatment of Pulmonary Arterial Hypertension | publisher = [[Gilead Sciences]] | date = 2007-06-15 | url = http://www.gilead.com/wt/sec/pr_1016053 | access-date = 2007-06-16 | archive-url = https://web.archive.org/web/20070927064048/http://www.gilead.com/wt/sec/pr_1016053 | archive-date = 2007-09-27 }}</ref> |
| ====Phosphodiesterase type 5 inhibitors==== | ====Phosphodiesterase type 5 inhibitors==== |
Okumaya devam et...